YNYutaka Negishi

Yutaka Negishi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yutaka Negishi has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Trained immunity suppression determines kidney allograft survival

    by Inge Jonkman, Maaike M.E. Jacobs, Yutaka Negishi, Cansu Yanginlar, Joost H.A. Martens, Marijke Baltissen, Michiel Vermeulen, Martijn W.F. van Den Hoogen, Marije Baas, Johan van der Vlag, et al.


  • A chromatin-regulated biphasic circuit coordinates IL-1β-mediated inflammation

    by Ezio T. Fok, Simone J. C. F. M. Moorlag, Yutaka Negishi, Laszlo A. Groh, Jéssica Cristina dos Santos, Cathrin Gräwe, Valerie Villacorta Monge, Daphne D. D. Craenmehr, Mellanie van Roosmalen, David Pablo da Cunha Jolvino, et al.

    Inflammation is characterized by a biphasic cycle consisting initially of a proinflammatory phase that is subsequently resolved by anti-inflammatory processes. Interleukin-1β (IL-1β) is a master regulator of proinflammation and is encoded within the same topologically associating domain (TAD) as IL-37, which is an anti-inflammatory cytokine that opposes the function of IL-1β. Within this TAD, we identified a long noncoding RNA called AMANZI, which negatively regulates IL-1β expression and trained immunity through the induction of IL37 transcription. We found that the activation of IL37 occurs through the formation of a dynamic long-range chromatin contact that leads to the temporal delay of anti-inflammatory responses. The common variant rs16944 present in AMANZI augments this regulatory circuit, predisposing individuals to enhanced proinflammation or immunosuppression. Our work illuminates a chromatin-mediated biphasic circuit coordinating expression of IL-1β and IL-37, thereby regulating two functionally opposed states of inflammation from within a single TAD.